Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
Optimi Health has secured naturally derived ibogaine from two sources and will begin development of a finished drug product at its GMP facility in British Columbia this summer. The company plans to produce encapsulated ibogaine in 50mg and 100mg dosages, leveraging its existing Health Canada licensing and GMP infrastructure which also supports psilocybin and MDMA manufacturing.
Key figures
- Drug Name
- Ibogaine
- Dosage strengths
- ["50mg","100mg"]
- Texas funding program
- $50 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.